furazolidone has been researched along with Peptic Ulcer in 14 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 9.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 9.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 9.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 5.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 5.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 5.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| " pylori) is complex; full effectiveness is rarely achieved and it has many adverse effects." | 2.78 | Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. ( Barbuti, RC; Bogsan, CS; Chinzon, D; de Oliveira, MN; Eisig, JN; Mattar, R; Moraes-Filho, JP; Navarro-Rodriguez, T; Silva, FM, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (42.86) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Navarro-Rodriguez, T | 2 |
| Silva, FM | 3 |
| Barbuti, RC | 3 |
| Mattar, R | 1 |
| Moraes-Filho, JP | 1 |
| de Oliveira, MN | 1 |
| Bogsan, CS | 1 |
| Chinzon, D | 1 |
| Eisig, JN | 3 |
| Felga, GE | 1 |
| Zaterka, S | 1 |
| Xu, C | 1 |
| Xiao, L | 1 |
| Zou, H | 1 |
| Riahizadeh, S | 1 |
| Malekzadeh, R | 1 |
| Agah, S | 1 |
| Zendehdel, N | 1 |
| Sotoudehmanesh, R | 1 |
| Ebrahimi-Dariani, N | 1 |
| Pourshams, A | 1 |
| Vahedi, H | 1 |
| Mikaeli, J | 1 |
| Khatibian, M | 1 |
| Massarrat, S | 1 |
| Ghadir, MR | 1 |
| Shafaghi, A | 1 |
| Iranikhah, A | 1 |
| Pakdin, A | 1 |
| Joukar, F | 1 |
| Mansour-Ghanaei, F | 1 |
| Wang, F | 1 |
| Wang, XY | 1 |
| Jia, Y | 1 |
| Shen, SR | 1 |
| Xu, CX | 1 |
| Tang, WL | 1 |
| Liu, SJ | 1 |
| Chen, X | 1 |
| Rodriguez, TN | 1 |
| Hashimoto, CL | 1 |
| Zheng, ZT | 3 |
| Xiao, SD | 1 |
| Liu, WZ | 1 |
| Hu, PJ | 1 |
| Xia, DH | 1 |
| Tytgat, GN | 1 |
| Wang, ZY | 2 |
| Chu, YX | 2 |
| Li, YN | 2 |
| Li, QF | 2 |
| Lin, SR | 2 |
| Xu, ZM | 2 |
| Zhao, HY | 1 |
| Li, GZ | 1 |
| Guo, JD | 1 |
| Yan, Z | 1 |
| Sun, SW | 1 |
| Li, LS | 1 |
| Duan, YM | 1 |
| Yue, FZ | 1 |
| Howden, A | 1 |
| Boswell, P | 1 |
| Tovey, F | 1 |
| Shi, AS | 1 |
1 review available for furazolidone and Peptic Ulcer
| Article | Year |
|---|---|
[Advances in clinical observations and experimental research on peptic ulcer treated with traditional Chinese medicine and western medicine].
Topics: Acupuncture Therapy; Animals; DNA; Furazolidone; Humans; Medicine, Chinese Traditional; Medicine, Ea | 1985 |
11 trials available for furazolidone and Peptic Ulcer
| Article | Year |
|---|---|
Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Brazil; Disease Eradication; Double- | 2013 |
Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dr | 2008 |
[Effect of birid triple viable on peptic ulcer patients with Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug The | 2010 |
Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Double-Blind Meth | 2010 |
Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents | 2011 |
[Five-day rabeprazole-based triple therapy for helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Drug Administrati | 2004 |
[A double-blind short-term clinical trial of furazolidone on peptic ulcer].
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Furazolidone; Gastric Acid; Humans; Ma | 1984 |
High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Cla | 1999 |
Double-blind short-term trial of furazolidone in peptic ulcer.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Furazolidone; Humans; Male; Peptic Ulc | 1985 |
Furazolidone in peptic ulcer.
Topics: Adult; Cimetidine; Female; Furazolidone; Humans; Male; Peptic Ulcer; Pyridoxine; Vitamin K | 1985 |
A double-blind short-term clinical trial of furazolidone on peptic ulcers.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Furazolidone; Humans; Male; Peptic Ulc | 1985 |
2 other studies available for furazolidone and Peptic Ulcer
| Article | Year |
|---|---|
A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Local; Chi-Square Distribution; Cohort Studies; Conf | 2005 |
In-vitro sensitivity of Campylobacter pyloridis to furazolidone.
Topics: Campylobacter; Furazolidone; Humans; Peptic Ulcer | 1986 |